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Abstract: 
 
The era of precision medicine has arrived and conveys tremendous potential, particularly for stroke neurology. 
The diagnosis of stroke, underlying etiology, theranostic strategies, recurrence risk, and path to recovery are 
populated by a series of highly individualized questions. Moreover, the phenotypic complexity of a clinical 
diagnosis of stroke makes a simple genetic risk assessment only partially informative on an individual basis. 
The guiding principles of precision medicine in stroke underscore the need to identify, value, organize, and 
analyze the multitude of variables obtained from each individual to generate a precise approach to optimize 
cerebrovascular health. Existing data may be leveraged with novel technologies, informatics and practical 
clinical paradigms to apply these principles in stroke and realize the promise of precision medicine. 
Importantly, precision medicine in stroke will only be realized once efforts to collect, value, and synthesize the 
wealth of data collected in clinical trials and routine care commences. Stroke theranostics, the ultimate vision 
of synchronizing tailored therapeutic strategies based on specific diagnostic data, demand cerebrovascular 
expertise on big data approaches to clinically relevant paradigms. This review considers such challenges and 
delineates the principles on a roadmap for rational application of precision medicine to stroke and 
cerebrovascular health.     
        
  
Precision medicine is broadly defined as tailored diagnosis and therapy for each individual patient1. Driven by 
an explosion in genomic sequencing capabilities together with simultaneous revolutions in computing 
capabilities, recent years have seen the initial application of this approach take root in the practice of clinical 
medicine, though almost exclusively in the field of oncology. Recent nationwide efforts2 to expand precision 
medicine to many other areas of medicine have been promoted, including stroke3-6. The meaning of the 
application of precision medicine to a phenotypically diverse disease such as stroke, however, is far more 
complicated than the comparatively simple genomic identification of the disease-causing mutation in a cancer 
patient. Stroke is a basket term that historically includes multiple distinct disorders that acutely alter the 
nervous system. However, stroke phenotypes include widely disparate areas of neuroanatomy, the 
neurovascular tree, unique pathophysiology, and likewise span both acute and chronic time points. For 
example, stroke due to cerebral microvascular disease demonstrates considerable overlap with neurocognitive 
disorders7 8. Such phenotypic variation poses several challenges to the application of precision stroke 
medicine. Each of these phenotypic variations is associated with different types of input data that need to be 
appropriately and intelligently integrated to carry value in tailoring therapy during the acute, recovery, and 
prevention phases of cerebrovascular disease. These challenges underscore the value and importance of 
standardizing clinical, biologic (genomic, serologic, and novel), and imaging data collection, much of which is 
already collected during focused, hypothesis-driven, group-wise clinical trials yet not readily utilized. Moreover, 
true stroke precision medicine will require experienced and rational valuation of these multiple data points and 
appropriate statistical methodology to harness their collective potential for individualized decision-making. 
Stroke theranostics, the ultimate vision of synchronizing tailored therapeutic strategies based on specific 
diagnostic data, demand cerebrovascular expertise on big data approaches to clinically relevant paradigms. 
This review considers such challenges and delineates the principles on a roadmap for rational application of 
precision medicine to stroke and cerebrovascular health.     
 
CLINICAL DATA 
 
Standardized Methods 
Precision diagnosis and treatment require big data in numerous dimensions, considerable depth, extensive 
volume and high quality. Past clinical trials, however, collected a negligible fraction of the vast array of 
variables established in the NIH-defined Common Data Elements (CDE). The development of common data 
elements for inclusion in a given clinical trial and collection for future study provides a standard language to 
define what each variable reflects9. Precision stroke medicine requires rigorous standardization, definition of 
variables, consistent data collection, reliable central adjudication and, where appropriate, quantification10. 
Clinical variables require particularly meticulous definition to their preserve future value, as they may be 
identified by a wide spectrum of criteria, from spoken history to complex physiologic measurement. 
Standardization of clinical data elements permits data analysis across trials; the larger sample size creates 
power to study subgroups, which cannot be explored in single trials. 
 
Challenges in Data Collection 
A precision approach requires that data acquisition and analysis be made a central feature of trial design, 
requiring dedicated infrastructure independent of the focus on diagnostic method or treatment being studied. A 
potential foundation for such a sustainable and effective research model would include StrokeNet, the NINDS 
stroke trials network4 11. The breadth of data elements to be potentially collected in trial design has exploded, 
from a basic set of clinical variables to addition of imaging, physiologic, and genomic data. Even when specific 
markers or detailed datasets are of unproven value, source data collection must be structured within the 
framework of a trial and made available for future study. An unfortunate example of missed opportunity might 
include stroke imaging studies which failed to discern accurate stroke subtypes or ischemic infarct patterns, 
thresholds and volumes associated with distinct mechanisms. 
 
The location or environment where data are collected is as essential a consideration as the standardization of 
the data. Local collection of data elements in real time differs greatly from central adjudication of those 
variables. Consider an example from acute stroke imaging: the extent of early ischemic changes on CT or the 
degree of reperfusion may vary considerably between local and central readings. Local, real time readings by 
treating physicians enhance the generalizability of the data. Central adjudication by an imaging core lab 
provides reliability9. Generalizability may also be increased by collecting information regarding excluded 
subjects via screening logs and consideration of dropouts and withdrawal of care9. 
 
Temporal aspects of data ascertainment are also relevant. Specific variables may have different meaning 
depending on whether they were measured in the acute period of stroke onset or in the follow up of an acute 
stroke case and timing must be precisely identified. Clinical trials may refer to ‘admission’ values for NIHSS, 
yet it is not always reliably documented when this takes place. Since such measurements change considerably 
over time, detecting any fluctuation in these parameters may be critical in a stroke patient. Moreover, collection 
of data in prior trials presbyopically centered around timing of the investigational treatment, whilst ignoring 
prehospital, intensive care unit (ICU), or post-discharge periods up until the standard day 90 evaluation. This 
has limited the study of potentially critical treatment variables such as early hemodynamic management, ICU 
treatment, or rehabilitation therapies that influence clinical outcomes in stroke9. The use of serial, peri-
procedural multimodal imaging will increase, resulting in a huge number of variables. Long-term data storage 
also plays an essential role. Data archiving ensures maximal study interpretation and financial investment. 
Digital Imaging and Communications in Medicine (DICOM) imaging datasets and biological specimens, for 
example, could be tapped for decades. Collection of source imaging datasets allow for repeated analyses and 
has proven invaluable9. Raw data captured today can be stored and reanalyzed tomorrow given new software 
developments. A clinical trial network could archive routinely collected imaging data to keep pace with evolving 
imaging technology. Post-processing techniques such as computational fluid dynamics are novel, have been 
successfully applied to older datasets, but are continuously improved upon and replaced. Archived data have 
many lives4. Consider the potential of a neuroimaging library, functioning as a repository of lesion atlasing. 
Novel software can be tested in larger datasets and remote real time viewing and analysis can be developed. 
Similarly, collection of biological samples such as blood constituents do not require knowledge of every 
molecular signature, as storage of samples may be tapped decades later to identify novel findings.  
 
Clinical Utility 
The WASID trial of intracranial atherosclerosis illustrates the potential of a “data stored for future study” 
approach. Post hoc analyses of collaterals on conventional angiography were superior to the degree of arterial 
stenosis for predicting patient outcomes. Subsequent analyses also demonstrated that fractional flow 
measures were useful in predicting outcomes. In SAMMPRIS, the centrally collected imaging datasets 
provided the basis to validate the role of collaterals pioneered in the WASID trial. Thus, previous negative trial 
data in stroke provided fertile ground to examine subgroups from an imaging perspective, since the data were 
collected and stored. The role of breast-cancer gene-expression products in prognosis developed as a result of 
studies of preserved biologic tissues. Later retrospective studies of randomized, clinical trials suggested little 
benefit of chemotherapy in women having low recurrence risk. Now, prospective randomized trials study the 
effects of adjuvant chemotherapy stratified by predicted risk12.  
 
BIOLOGICAL DATA 
 
Biological Data - Genomics 
Genetics and genomics fueled the personalized medicine concept. For the first time in decades since the 
seminal deciphering of DNA structure, the reality of gene therapy and genome editing for monogenic disorders 
is closer than ever13 14. However, stroke as a phenotype is considered to be a “complex genetic trait,” i.e., 
influenced collectively by numerous genetic variants with individually small effect sizes, and the search for 
specific stroke genes remains a work in progress. There are very few stroke syndromes that are considered 
“genetic;”15 in fact, while stroke is known to run in families, a component of shared environment is likely to 
modify the heritability contribution seen in twin and family history studies16. Genetic contribution is probably 
stronger in younger individuals with stroke, as well as in those with hemorrhagic stroke subtypes and non-
cardioembolic (non-CE) ischemic stroke17; furthermore, there is also suggested shared genetic contribution 
between large artery atherosclerosis (LAA) and small vessel (SV) ischemic stroke subtypes as shown recently 
in large-scale genetic studies of patients with ischemic stroke18.  
 
Diagnosis of stroke often involves a combination of clinical formulation (based on the semiology and timeline of 
a presenting syndrome), results of neurological examination and neuroimaging. Current challenges to the role 
of genomics in clinical stroke diagnoses are imposed by the rapid workflow of acute stroke therapy and the 
untouched, yet unmet need for personalized secondary stroke prevention. Gene expression profiling, a 
genomic approach based on interrogation of RNA molecules circulating in peripheral blood has demonstrated 
early promise in differentiation of ischemic stroke from acute non-stroke pathologies (such as myocardial 
infarction and seizures), as well as intracranial hemorrhage and transient ischemic attack19. Furthermore, 
specific genome-wide RNA signatures might exist for individual ischemic stroke subtypes such as CE vs. LAA, 
and lacunar vs. non-lacunar strokes19. While gene expression profiling has not yet been incorporated into 
current clinical routine in the era of hyperacute diagnosis, the rationale for using rapid, accurate, and 
inexpensive point-of-care testing to improve precision of stroke subtyping is compelling. Beyond the acute 
phase, accurate determination of stroke etiology is an important step toward therapeutic management, 
personalized risk stratification, and formulation of a secondary stroke prevention strategy for each individual 
patient20. 
 
Once a diagnosis of acute stroke is established, treatment options and outcome prediction become a priority.  
For stroke syndromes associated with well-established underlying genetic disorders such as cerebral 
autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), mitochondrial 
encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) or Fabry disease (FD), targeted genetic 
counseling (CADASIL), disease-specific interventions (MELAS), or enzyme-replacement therapy (FD) now 
exist15 16 19. In patients with lobar intracranial hemorrhage, presence of APOE gene mutation (ε2 or ε4 allele) 
suggests an increased risk of recurrent hematoma and may guide personalized selection of antithrombotics16. 
For individuals with Marfan-like features, stroke, and elevated homocysteine, mutational screening in the CBS 
gene may help identify homocystinuria and guide theranostics15.  
 
Beyond monogenic syndromes, there is a growing field of pharmacogenetics, i.e. the study of genetic variation 
in drug response, which is applicable to large populations of stroke patients. In an era of targeted management 
of vascular risk factors, individual response to antithrombotics, statins, and even drugs commonly used to 
control blood pressure and diabetes mellitus is often tested through trial and error, rather than theranostics21.  
There is evidence that a large proportion in response variability to warfarin may be explained by common 
genetic variants in VKORC1 and CYP2C9 genes, prompting specific FDA dose recommendations. Similarly, 
the CYP2C19*2 variant was associated with reduced concentrations of clopidogrel in blood and increased risk 
of cardiovascular events in its users, prompting the FDA request for a black-box warning regarding reduced 
effectiveness in poor metabolizers. For the direct thrombin inhibitor dabigatran, a polymorphism CES1 
(rs2244613) was noted to reduce drug concentration by 15% and decrease risk of bleeding by 33%22. A 
number of genetic variants have also been identified in association with individual patient response to other 
stroke-specific classes of drugs (such as statins or anti-hypertensive agents), supporting the need for precision 
stroke medicine and theranostic development21. 
 
In acute stroke, evidence of genetic influence on individual response to alteplase is emerging, with variants in 
A2M (rs669) and F12 (rs1801020) being linked to hemorrhagic transformation and in-hospital death23. 
Currently, genetic architecture of post-stroke outcomes is poorly understood; however, translational studies of 
genetic variability in cerebral murine collateral circulation may prove important in understanding 
pathophysiology of collateral response in acute ischemic stroke24. Similarly, the ongoing investigations of 
leukoaraiosis, a highly-heritable neuroimaging trait associated with increased risk of stroke and poor post-
stroke outcomes hold promise for insight into mechanisms of brain susceptibility to acute ischemia25.  
 Pursuing complex genetic underpinnings of stroke across the spectrum of clinical applications in precision 
medicine (i.e., diagnosis, treatment, prognosis, and prevention) will require large-scale, high-throughput 
studies that are based on thorough phenotype ascertainment and cutting-edge methodology including 
genome-wide genotyping, whole-genome (and/or exome) sequencing, and gene expression studies.  In 
addition, systematic strategies to translate genetic discovery into clinically relevant applications are urgently 
needed. If fully integrated, a personalized approach in stroke incorporating genetics and genomics may 
improve precision diagnosis; streamline treatment options that are safe and effective; and boost the predictive 
ability of risk and outcome models in stroke. 
 
Biological Data – Serologic 
Blood biomarkers have been used for many years in other vascular conditions, such as troponins for 
myocardial infarction diagnosis, glycosylated hemoglobin for diabetes monitoring, or low-density lipoprotein 
cholesterol level for starting lipid-lowering therapies, yet no biomarker is routinely used in stroke management 
either for diagnostic, prognostic or risk-stratification purposes. Recently, there has been great interest in the 
potential of serologic markers of neurovascular disorders, from predicting stroke risk among healthy individuals 
to establishing a biochemical diagnosis of stroke or in using biomarkers as tools for outcome prediction. 
 
Most surrogate biomarkers in stroke are focused on underlying pathophysiology, such as inflammation and 
immune system response, apoptosis, coagulation and fibrinolysis, tissue remodeling or heart damage. 
Recently, enthusiasm has mounted for high-throughput techniques based on a large screening process, 
avoiding selection bias and generating extensive lists of molecules to be evaluated. Among the new -omics 
techniques, proteomic studies (the study of the entire set of proteins expressed by a genome under a particular 
situation) are still the most promising tools for discovering new biomarkers, as proteins are the most widely 
used biomarkers and easily detectable in quick point-of-care devices. In fact, due to the complexity of the 
nervous system, proteomic tools have been invaluable in terms of biomarker and disease target discovery 
directly in the brain26. However, taking into account that blood is employed as the most suitable biological 
sample, a whole proteome approach could be addressed with mass spectrometry-based techniques thus 
covering a wide number of proteins directly in the serum or plasma. Alternative proteomic techniques are 
required for discovery of small specific indicators of disease, as identification of clinically significant biomarkers 
is challenged by the presence of tens of thousands of circulating proteins and differences in protein abundance 
ranging up to eleven orders of magnitude. Antibody libraries and protein arrays are promising but still 
expensive to conduct in large studies27.  
 
Precision stroke medicine may be enhanced with blood biomarkers for predicting stroke risk, complementing 
subtype diagnosis and refining prognosis. Key priorities include prediction of stroke risk among healthy people, 
among those with vascular risk factors and identification of silent ischemic brain lesions; diagnosis of stroke 
and transient ischemic attack (TIA); differentiation between stroke subtypes (ischemic versus hemorrhagic), 
between ischemic stroke etiologies; evaluation of response to reperfusion therapies; prediction of the global 
prognosis of stroke and of specific complications of stroke; and evaluation of secondary prevention strategies 
(see http://stroke-biomarkers.com/).  
 
FDA has approved the use of lipoprotein-associated phospholipase A2 (PLAC test) to predict risk of stroke 
developing among healthy individuals. Lp-PLA 2 is a serine lipase, which circulates mainly linked to low-
density lipoproteins known to be a good predictor of both first-ever and recurrent strokes in population-based 
studies. Such strategies will allow increasing vascular prevention strategies among the highest risk people. 
 
Rapid biochemical diagnosis that would help distinguish stroke mimics may streamline triage of the right 
patients to stroke centers. The idea of identifying the "troponins" of stroke has encouraged several groups and 
biotechnology companies to initiate such discovery programs, yet a robust, sensitive and rapid blood test is still 
lacking. Similarly, a prehospital or bedside rapid diagnostic test to differentiate ischemic and hemorrhagic 
stroke is desirable. Rapid differentiation may enable initiation of tailored pre-hospital therapies, such as blood 
pressure lowering in ICH, rapid reversal of anticoagulation in the presence of warfarin-associated ICH or 
delivering tPA to ischemic stroke patients in the field. Although prehospital acute stroke treatment is becoming 
reality28, implementation of resource-intensive approaches with portable CT are difficult and blood biomarkers 
may play a role, especially in low-income countries. Examples of such biomarkers include glial fibrillary acidic 
protein (GFAP), or RBP4 that is as a promising biomarker to distinguish ischemia from hemorrhage when 
combined with GFAP and others29. 
 
Serologic biomarkers may refine determination of stroke etiology and classification, as many patients currently 
receive a diagnosis of undetermined stroke. For example, increased blood levels of natriuretic peptides (B-type 
natriuretic peptide or N-terminal pro-BNP) have been repeatedly associated with CE stroke30. In the future, the 
use of blood biomarkers will allow clinicians to rapidly guide other diagnostic tests and accelerate initiation of 
tailored secondary prevention. 
 
Blood biomarkers may clarify extreme variations in stroke prognosis, commonly influenced by numerous 
factors such as age, stroke severity, co-morbidities and complications. Early prediction of complications, such 
as cerebral edema, hemorrhagic transformation, or post-stroke infection represents a unique opportunity to 
improve stroke outcome. Early detection seems feasible by combining clinical, imaging and biological data 
(such as IL6, copeptin, endostatin) but advancing such algorithms in routine clinical practice requires proper 
data integration strategies and further research. Furthermore, blood biomarker levels should be linked not just 
with general measures of prognosis such as disability or death, but with specific causes of worsening that 
culminate in poor outcome. Several studies have focused on biomarkers of stroke-associated infections such 
as IL-6, the Th1/Th2 profile, copeptin, procalcitonin or the recently described SAA31. However, the accuracy, 
sensitivity and specificity of all these biomarkers are still not adequate for clinical use. Moreover, lack of 
common criteria for the outcome endpoint (e.g. post-stroke pneumonia), further thwarts the ability to identify 
proper blood biomarkers32. Even before clinical implementation, semi-interventional trials are necessary to link 
a biomarker with a specific intervention, such as the STRoke Adverse outcome is associated WIth NoSocomial 
Infections trial33, which is evaluating the use of a biomarker guided (ultrasensitive procalcitonin) strategy in the 
indication of preventive antibiotic therapy in patients with severe stroke. 
 
Theranostics of blood biomarkers beyond genetic propensity noted above may be used to refine treatment 
response, as patients respond differently to thrombolysis and mechanical reperfusion strategies. Serologic 
biomarkers may selectively evaluate tPA response, prediction of hemorrhagic transformation, and identify 
patients with unsuccessful tPA-induced recanalization. In terms of hemorrhage, fibronectin, MMP-9 and VAP-1 
are considered potential biomarkers34 35, yet a large cohort study that combines such measures is lacking.  
 
Implementation of serologic biomarkers in routine clinical practice remains a major challenge. A limiting factor 
is the extended period required for validation and commercialization of a discovered biomarker. The search for 
novel stroke biomarkers should therefore leverage other data types to accelerate development.  
 
Novel Biological Data 
Beyond the obvious potential for added diagnostic and prognostic value afforded by genomic and serologic 
data, additional biologic specimens collected from patients may add precision to the diagnosis of individual 
cases. These range from routine analysis of CSF and brain biopsy samples in selected cases36 to samples 
uniquely available from stroke patients such as histologic and proteomic analysis of clots retrieved during 
thrombectomy37 and cerebrovascular endothelial cells that can be captured from stent retrievers after use in 
thrombectomy38. Though presently these additive biologic variables are not routinely utilized, they hold the 
potential to unlock additional diagnostic, prognostic, and theranostic value.   
 
IMAGING DATA 
Neuroimaging of the brain and related vascular structures remains the foundation for determination of stroke 
etiology. Imaging data are routinely acquired in every potential stroke patient, providing a wealth of data on 
cerebrovascular health and evolution of active pathophysiology. The phenotype of stroke, reflecting 
contributions from multiple genes and additional influences such as lifestyle and environmental factors, cannot 
be ascertained without imaging. While studies on stroke genomics are still at a rudimentary stage of searching 
for susceptible loci or genes associated with each subtype of stroke, one pre-requisite for the success of these 
genetic studies is a ‘precise’ stroke etiology or subtype. Single nucleotide polymorphisms (SNP) or variants 
that each contribute modestly to the phenotype would remain obscure if the stroke subtype classification is 
rough or imprecise. In fact, imprecise stroke subtyping has already led to a large number-needed-to-treat in 
conventional stroke treatment studies when a minority of study participants drove the cohort effect. Large 
artery atherosclerosis (LAA), most common stroke etiology around the world, provides such an example. 
Based on TOAST classification, cerebral ischemia attributed to atherosclerosis of either the extracranial 
internal carotid artery or intracranial arteries have been collectively grouped as LAA. However, LAA does not 
focus on the location and functional impact of atherosclerosis, a critical factor in governing prognosis and 
related treatments. In fact, based on the site of symptomatic lesion, LAA strokes broadly fall into two relatively 
distinct phenotypes, extracranial carotid artery disease (ECAD) and intracranial atherosclerotic disease (ICAD). 
Compared with ECAD, ICAD has a significantly higher rate of early relapse.  Moreover, ICAD and ECAD 
respond differently to the same treatment strategy. For instance, angioplasty/stenting proven effective for 
ECAD was found even inferior to medical treatment for ICAD. Epidemiologically, the diverging prevalence of 
ECAD versus ICAD in Caucasians, Asians, Hispanics and Blacks strongly suggests a genetic contribution and 
a distinction between these entities currently lumped as LAA. If a genomic investigation on LAA 
indiscriminately recruits both ICAD and ECAD patients based on TOAST classification, it will dilute any 
potential power in detecting an associated variant. Hence, TOAST is not ‘precise’ enough for current clinical or 
research purposes. However, would the Causative Classification of Stroke (CCS), an improved version of 
TOAST classification, be precise enough for risk prediction or treatment allocation? CCS now permits 
distinguishing patients with symptomatic ICAD from patients with symptomatic ECAD. Nevertheless, ICAD can 
cause ischemic strokes through multiple stroke mechanisms: artery-to-artery thromboembolism from unstable 
plaques; occlusion of penetrating artery ostium by a clot or atheroma; Venturi effect causing hypoperfusion of 
perforators; high-grade steno-occlusion leading to cortical ischemia; or a combination of these (e.g. 
thromboembolism with impaired washout at borderzones). Without understanding the ‘precise’ stroke 
mechanism in each individual ICAD patient, treatments that have been designed with a ‘one-size-fits-all’ 
approach may be useful for some patients but not helpful or even harmful for others. For example, an ICAD 
patient with ipsilateral hemispheric hypoperfusion may benefit from angioplasty of middle cerebral artery 
stenosis; but the same endovascular procedure may pose a significant risk of perforator stroke if one does not 
appreciate the concurrent presence of branch atheromatous disease adjacent to the stenosis. 
 
The dynamic nature of either intracranial or extracranial atherosclerotic plaques further complicates precise 
strategies. An apparent high-grade stenosis at the acute stage may regress significantly after stringent control 
of cardiovascular risks; yet some lesions may contrarily continue to progress, despite treatment. Hence, the 
current approach of relying on a single scan or imaging snapshot of a vascular lesion is inadequate to portray 
phenotype. Serial imaging data, or repeated evaluations over time, that reflect the temporal nature of 
cerebrovascular disorders may elucidate the homeodynamics that govern the evolution of collaterals, cerebral 
autoregulation and infarct expansion. Similar ‘imprecision’ or ambiguity in diagnosis may also occur in other 
TOAST subtypes. For example, a small artery-to-artery thromboembolic infarct from LAA may be classified as 
a lacunar infarct or small vessel disease based on TOAST if vascular imaging is inadequate.  
 
Brain imaging has the capacity to identify viable tissue and thus select patients most likely to benefit from 
interventions, especially reperfusion. The concept was demonstrated using positron emission tomography in 
the 1990s, when clinically similar acute patients were found to fall into three groups based on imaging 
findings.39 One group with severely reduced blood flow accompanied by failure of oxygen utilization had 
uniformly poor outcome; one with preserved blood flow and oxygen utilization had uniformly good outcome; 
and the third group, with variable outcome, had hypoperfusion but preserved metabolic capacity. This last 
group was believed to demonstrate imaging features of the ischemic penumbra40, and to represent a suitable 
target group for interventions such as reperfusion therapies. Subsequent developments of technology have 
translated this concept into more usable technologies, primarily CT perfusion and MRI.41 It is generally 
accepted that tissue with probability of infarction regardless of reperfusion, the ischemic core, is denoted by the 
diffusion weighted MRI (DWI) lesion, and by significantly reduced cerebral blood flow (CBF) or cerebral blood 
volume (CBV) on CT perfusion. The core is likely also represented by visible hypodensity on non-contrast CT 
(NCCT), although with much lower sensitivity compared to DWI or CTP. Potentially viable penumbra is defined 
by hypoperfusion, identified as tissue with prolonged contrast transit (but normal DWI signal on MRI, “diffusion-
perfusion mismatch,” or normal CBF or CBV on CTP), various definitions employing different time-based 
metrics including mean transit time (MTT), time to peak (TTP), delay time (DT) or time to the maximal tissue 
contrast peak (Tmax).42  
 
Patient selection by imaging increases clinical trial efficiency since it increases the likelihood of selecting a 
responder population (and is rooted in pathophysiology), excluding those with either no need for treatment or 
no likelihood of benefit. Calculation of hypothetical sample size for clinical trials shows substantial reductions in 
sample size with an imaging-selection approach.43 The penalty is of fewer eligible patients and slower 
recruitment. Observational data support the concept that reperfusion of patients with imaging selection is 
beneficial whereas reperfusion of patients lacking an imaging target is not;44 data also suggest possible 
increased risk of hemorrhagic transformation when reperfusion occurs in the face of extensive irreversible 
ischemia (the “large core” group with >70ml core tissue).45 
 
Recent clinical trials deploying imaging selection for reperfusion treatment have shown larger benefits than 
similar trials without tissue imaging selection. Examples include tissue selection in a tenecteplase trial,46 
showing superiority over alteplase, while a trial without tissue selection criteria did not demonstrate benefit;47 
and the endovascular thrombectomy trials deploying perfusion selection 48 49 having a larger treatment effect 
than those without.50 51 A strategy for penumbral imaging selection to maximize clinical trial efficiency needs to 
be distinguished from evidence of any given treatment being ineffective in those being excluded; indeed, the 
exclusion of patients from clinical trials may impede our understanding of clinical application of an intervention. 
Proportional benefits from intravenous thrombolysis or endovascular thrombectomy do not appear to differ 
among those with more extensive NCCT hypodensity or CTP-defined large core,52 within the constraints of 
fulfilling other trial eligibility criteria and small numbers being recruited at the severe end of the spectrum. 
Absolute benefits are lower and therefore there may be either a clinical or health economic case for limiting 
treatment in such patients. There are nonetheless further issues that should be addressed before basing a 
precision medicine approach on penumbral imaging. While observational studies of intravenous thrombolysis 
note better clinical outcomes among those with a “target mismatch” profile on CTP compared to historical 
control subjects treated on the basis of non-contrast CT alone,53 two pertinent factors require consideration. 
First, there is substantial disagreement between clinical interpretation of what constitutes an appropriate 
penumbral pattern and automated software analysis.53 Software analyses are not standardized and competing 
systems are used in different studies. Second, the additional time incurred in acquisition, processing and 
review of additional perfusion imaging may delay treatment, and since there is rapidly diminishing benefit from 
both intravenous thrombolysis and endovascular thrombectomy over short time intervals54 55, such delay may 
be detrimental.56 The use of advanced multimodal imaging at local sites with central telestroke triage offers 
another example of how a precision medicine approach to imaging acquisition, data transfer, automated post-
processing, and clinical decision-making tools may be used in the future. 
 
STRATEGIES FOR DATA INTEGRATION 
 
Data selected for precision medicine need not be strictly molecular or imaging based. Epidemiological 
precision medicine utilizes large data sets, such as administrative claims. The Observational Health Data 
Sciences and Informatics collaborative uses electronic health records and health insurance claims data. 
Diverse data sources and large sample sizes inherent in this approach have the potential to improve the 
derived prognostic models.  
 
Using Clinical Expertise to Value Data 
Success in precision stroke medicine requires that investigators advance from identifying risk factors that are 
merely associated with outcomes to clinical features rooted in pathophysiology that actually cause outcomes. 
For example, baseline stroke severity is a prominent determinant of outcome, while collateral circulation 
determines stroke severity and is based in the pathophysiology that determines the spectrum of stroke severity 
outcomes. It is not surprising that imaging collateral flow before treatment of ischemic stroke has become 
increasingly important9. Similarly, the spot sign, reflecting potential contrast extravasation on CTA, predicts 
early intracerebral hematoma growth and reflects underlying pathophysiology. Perfusion delays are 
increasingly analyzed in acute stroke, but the context in which they occur likely affects their interpretation. In a 
population of acute stroke patients with intracranial atherosclerosis, perfusion delays identified on CTP or PWI 
are likely chronic, thus limiting their value4. 
 
Presence versus Degree 
Statistical analyses and clinical interpretability often require a sacrifice of precision in that a data parameter be 
changed from a continuous variable and dichotomized into “present or absent” or “high or low.”12 In acute 
stroke, despite decades of research, the concept of ischemic penumbra continues to be clarified. The methods 
of data definition, collection, storage and analysis inherent in precision medicine must lead to large, high 
quality datasets and new analytic methods if this tension is to be relieved.  
 
Reference Standards 
Cardiologists put fractional flow reserve (FFR) on the clinical map with invasive, pressure sensitive wires. Over 
time, they advanced to CTA based computational fluid dynamics to measure the same parameters. 
Neurologists need to be equally flexible in accepting non-invasive methods of data acquisition and advanced 
software methods in order to develop more practical approaches to investigation and new reference 
standards4. If large datasets originating in multiple locations are to be gathered in precision medicine, it is clear 
that owing to variability in availability of multimodal CT and MRI, cross-modality interpretation of various 
neurovascular imaging features will also be important10. 
 
Statistics, Incremental Value and Shared Decision Making 
While data are increasingly collected in precision medicine with new technologies, their introduction into the 
clinical arena still follows a common process. Investigators still ask whether a test reliably measures what it 
seeks to measure. Analyses of large datasets or randomized trials are performed to characterize clinical utility. 
Then, new tests are scrutinized for their incremental value: what do they add to previously used decision tools? 
This explosion of data will not be easy for scientists or patients to absorb and utilize. New approaches to data 
presentation, risk quantification, and communication of uncertainty are urgently needed12. It is becoming 
increasingly clear that the patient’s perspective must be accounted for if the promise of precision medicine is to 
bear practical fruit. 
 
Embedding Data Collection into RCT Design 
Integrating the principles of precision medicine with the logistics of clinical trials for stroke will require a shift in 
philosophy from the broad -- not to the narrow, but to the precise. Large trials in stroke, especially those 
conducted with the objective of regulatory approval, typically focus on comparisons of performance between 
treatments (or between treatment and no treatment), while including the widest possible population in which an 
advantage is expected to be observed with the investigational therapy. Such trials often enroll a heterogeneous 
population in which the observed treatment effect is really not a single effect but an average across patients 
who may have benefitted greatly and others who benefitted less, or not at all, from the investigational therapy. 
This paradigm is understandable and sometimes necessary – for instance, to justify the expense of a trial 
conducted by a commercial entity, the greatest return on investment will be sought, and the broadest plausible 
study population will therefore be enrolled. However, this runs counter to the objective of personalizing 
medicine. In a large trial, subgroup analyses may be feasible to evaluate risk and benefit, but even when the 
sample size is sufficient to permit meaningful subgroups, differences in response among those subgroups are 
often not of interest to the trial sponsor. Indeed, in a commercial setting the sponsor is actually discouraged 
from thoroughly seeking such differences lest a subgroup with poor response be found: the result of such a 
finding is likely to be a narrowing of the resulting regulatory label.  Few studies are therefore appropriately 
statistically powered to investigate populations below the mass of “all enrolled subjects.” The most useful 
change in focus is not simply to narrow the population under study. A clinical trial focused on a smaller, more 
homogeneous population may be able to answer specific questions about treatment outcomes impossible to 
find in broader investigations, but it cannot effectively extrapolate beyond its inclusion criteria.  For instance, a 
trial enrolling only subjects for whom tPA is unavailable as an option, or only those patients who are treated 
particularly quickly after stroke onset, by definition cannot offer reliable evidence about outcomes in other 
cohorts of patients. From the perspective of precision medicine, one type of desirable study design is therefore 
one which plans enrollment of a broad population, but also collects data which clearly identify potentially useful 
phenotypes and which prospectively mandates analyses designed to distinguish outcomes in one subgroup of 
patients from another.  Such a trial must necessarily be exploratory in nature, since if only thoroughly vetted 
hypotheses are tested, then truly novel, unplanned findings cannot arise. 
 
Analysis Techniques: Statistics for Precision Stroke Medicine 
In order to embrace the exploratory nature of such trials, methods of analysis that make the greatest use of 
such data must be considered.  As noted above, statistical methods in stroke trials commonly focus on 
distinguishing differences in outcome between alternative treatments, with the p-value comparing groups 
deemed paramount. In the past, analysis has often started with dichotomization of multivariate or continuous 
endpoints, such as the compression of the seven-point modified Rankin scale to a binary outcome of success 
or failure based on a cutpoint. Such approaches are intuitively appealing and comparatively easy to 
summarize, but they discard information in favor of simplicity.  Precision medicine will instead require analysis 
methods designed to retain maximum information and flexibility in pattern recognition.  Initial moves toward the 
comprehensive over the intuitive have already been seen, including the use of ordinal or “shift” analyses 
incorporating the full distribution of Rankin scores in recent trials of mechanical thrombectomy. To uncover new 
relationships, the data will have to speak for itself, and learning must also accumulate over time.  For this 
purpose, the Bayesian analysis paradigm should be emphasized. While Bayesian methods are not new to 
clinical trials, including stroke, they have often been utilized merely as a technique for reducing sample size, 
thereby reducing the burden of trial management. The true value of Bayesian analysis is in its ability to 
continuously adapt by incorporating new information, as opposed to the traditional, frequentist approach to 
data analysis, in which trials start without inferential information. Fully Bayesian methods also avoid the use of 
p-values entirely, which is appealing in an environment in which hypotheses may initially be vague, and where 
promising patterns of information should not be discarded because of a failure to achieve traditional statistical 
significance.  Similarly, statistical methods which prioritize pattern recognition over formal hypothesis testing 
will play a prominent role: methods such as nonparametric analysis, classification and regression trees and 
discriminant analysis can all be expected to appear more commonly than in past analysis approaches. 
 
Pathophysiology as Target 
The overwhelming focus on treatment effect must shift to studying the influence of baseline pathophysiology in 
the precision medicine world. The results of MR-RESCUE show that outcomes may be better predicted by 
baseline imaging of pathophysiologic states. Patients with a favorable penumbral pattern had improved 
outcomes, smaller infarct volumes, and attenuated infarct growth, as compared with patients with a non-
penumbral pattern, regardless of treatment assignment. Anatomic selection criteria have enjoyed a long history 
in stroke trials, especially the measurement of percent stenosis. Emphasis on function rather than structure is 
likely to be more fruitful. A recent study of cerebrovascular FFR in WASID/SONIA revealed that an entire group 
of patients excluded from SAMMPRIS, those with 40–69% anatomic stenosis, have a high stroke risk when 
baseline physiology rather than anatomy is used for patient selection. Yet, these patients have not been 
enrolled in aggressive clinical trials. Thus, novel imaging approaches may extend useful treatments to wider 
populations of patients. Anatomic selection may identify select patient groups believed to harbor similar risk but 
which turn out to have highly variable risk when selected by more precise functional measures available from 
imaging studies. Too often, imaging data are merely inclusion criteria--if all patients are enrolled because they 
harbor a specific imaging finding, that trial cannot determine whether the imaging approach that detected that 
finding was beneficial, as there is no comparison group. The efficiency of a clinical trial can be increased if 
patients are randomized to different imaging approaches or results, prior to randomization to treatment, as in 
MR-RESCUE or the cardiology studies of FFR: FAME and FAME II4. Perhaps various therapies may be 
combined and studied in a clinical trial where the main axis is defined by the underlying pathophysiology. 
Redesigning clinical trials around baseline pathophysiology using an adaptive trial model57 may improve our 
knowledge of natural history and hence individualized treatment effect, rather than the tradition of testing one 
therapy across heterogeneous patterns of influential pathophysiology.  
 
EXAMPLES OF FUTURE APPLICATIONS 
Recent advances in three-dimensional printing and biofabrication techniques may make it theoretically possible 
to develop precise, imaging-derived representations of cerebral aneurysms, intracranial stenoses, or the 
microvascular circulation ex vivo. This type of platform could easily be used to study how individualized 
genomic, serologic, and imaging variables described above might contribute to cerebrovascular occlusion on 
an individual level. With ready availability of such models and the increasingly faster ability to produce precise 
models that reflect individual patient characteristics, stroke precision medicine may become a reality. Imagine 
when a neurointerventionalist can approach each patient's aneurysm with not only a forethought treatment 
plan, but a trial and error tested approach; or a stroke neurologist can advise a patient with an intracranial 
stenosis or diffuse white matter microvascular disease, more precisely what their risk of recurrence is on a 
specific drug regimen. By wisely incorporating the principles of precision medicine together with the already 
accumulated and yet to be realized patient variables, true stroke precision medicine becomes imminently 
achievable and is likely to reduce cost long-term.     
 
CONCLUSION 
Relatively concurrent explosions in data collection, genomics, computing, and a multitude of advances in 
stroke research have preface the realization of precision medicine in stroke. Implementing this concept in 
practice, however, will require a multidisciplinary effort to bring together experts in traditionally disparate 
disciplines within the stroke field. True stroke precision medicine will require accurate clinical phenotyping, 
genomic and proteomic expertise, spatial and temporal imaging analysis, incorporation of new biologic 
variables, and the statistical and experiential knowledge to help assign the appropriate weight to each variable 
(Table 1). Though daunting, patients already think of medical decision-making in personal terms that 
increasingly demand individualized precision. There is nothing more powerful than being able to convey to a 
patient a precise diagnosis and treatment plan, never more so than in stroke when the outcome in question is 
not only mortality but physical and mental disability. Proper consideration of how one might apply the principles 
of precision medicine to stroke presages a new era of individualized therapy in stroke. 
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